793 abstracts found.



Results filter

Meeting the social care needs of people affected by cancer in Lincolnshire

Year:

Session type:

Theme:

David Nelson1,Ros Kane1

1University of Lincoln, Lincoln, Lincolnshire, UK


A POETIC story: lessons learnt from the world’s largest breast cancer window of opportunity study.

Year:

Session type:

Theme:

Judith MBliss1,A Gillman1,L Kilburn1,J Morden1,K Sidhu2,M Wilcox3,A Evans4,C Holcombe5,K Horgan6,A Skene7,R Vidya8,J Robertson9,M Dowsett2,IE Smith2

1Institute of Cancer Research, London, UK,2Royal Marsden Hospital, London, UK,3Independent Cancer Patients’ Voice, London, UK,4Poole Hospital, Poole, UK,5Royal Liverpool University, Liverpool, UK,6Leeds General Infirmary, Leeds, UK,7Royal Bournemouth Hospital, Bournemouth, UK,8Stafford Hospital, Stafford, UK,9Nottingham University Hospitals, Nottingham, UK


Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE(NCT00268476)

Year:

Session type:

Theme:

Nicholas D James1,13,Matthew R Sydes2,Malcolm D Mason3,Noel W Clarke14,David P Dearnaley4,Melissa R Spears2,Robin Millman15,Christopher C Parker8,Alastair W S Ritchie2,J Martin Russell5,John Staffurth11,Robert J Jones5,Shaun P Tolan6,John Wagstaff7,Andrew Protheroe8,Rajaguru Srinivasan9,Alison J Birtle10,Joe M O’Sullivan11,Richard Cathomas12,Mahesh K B Parmar2

1University of Warwick, Coventry, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Velindre Hospital, Cardiff, UK,4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK,5Beatson West of Scotland Cancer Centre, Glasgow, UK,6Clatterbridge Cancer Centre, Wirral, UK,7South West Wales Cancer Institute, Swansea, UK,8University of Oxford Medical Oncology Department, Oxford, UK,9Royal Devon and Exeter NHS Foundation Trust, Exeter, UK,10Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,11Belfast City Hospital, Belfast, UK,12Kantonsspital Chur, Chur, Switzerland,13Queen Elizabeth Hospital, Birmingham, UK,14The Christie and Salford Royal Hospitals, Manchester, UK,15Prostate Cancer Support Group, Middlesbrough, UK


Genes within the 3q26-29 amplicon present novel therapeutic candidates for oral cancer

Year:

Session type:

Theme:

Matthew Davidson1,Lynn McGarry1,Daniel James1,Emma Shanks1

1Cancer Research UK Beatson Institute, Glasgow, UK


Letters of condolence: assessing attitiudes and variability in practice amongst oncologists in Yorkshire

Year:

Session type:

Theme:

Jessica Hayward1,Oluwatobi Makinde1,Naveen Vasudev1

1University of Leeds, Leeds, UK


The Long-Term And Late Effects Of The Diagnosis And Treatment Of Colorectal Cancer

Year:

Session type:

Theme:

Andrew Carlile1,Nicola Gray1,Neil Campbell1,Leslie Samuel1

1University of Aberdeen, Aberdeen, UK


A clinical correlation study of ALK-rearranged circulating tumour cell subsets under crizotinib therapy – to assess for their potential role as predictive biomarkers in non-small-cell lung carcinoma

Year:

Session type:

Theme:

Emma Pailler1,2,Kirsty Ross1,2,Marianne Oulhen1,2,Fanny Billiot1,2,Colin Lindsay1,2,Nathalie Auger3,Philippe Vielh4,Isabel Borget5,Jean-Charles Soria6,David Planchard6,Benjamin Besse6,Francoise Farace1,2

1University of Paris-Sud, Gustave Roussy, Paris, France,2Translational Research Laboratory, Gustave Roussy, Paris, France,3Department of Biopathology, Gustave Roussy, Paris, France,4Department of Pathology, Gustave Roussy, Paris, France,5Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France,6Department of Medicine, Gustave Roussy, Paris, France


The Prechemotherapy Neutrophil-to-Lymphocyte ratio predicts survival in locally advanced/metastatic pancreatic carcinoma

Year:

Session type:

Theme:

Jyothsna Chennupati1,Charles Candish1,Sean Elyan1,Nicholas Reed1

1Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK


Outcomes of radioiodine remnant ablation in differentiated thyroid cancer

Year:

Session type:

Theme:

Jyothsna Chennupati1,Charles Candish1

1Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK


Quality Assurance (QA) of Radiotherapy Planning: Optimising the Peer Review process in a Canadian Cancer Centre

Year:

Session type:

Theme:

Joanna Mackenzie1,Gillian Graham1,Ivo Olivotto1

1Tom Baker Cancer Centre, Calgary,Alberta, Canada


Pattern of expression of ER/PR in 534 invasive breast cancer cases and rate of recurrence and disease progression in 211 invasive breast cancer cases who are on treatment based on traditional  prognostic factors in Addis Ababa University Teaching  Hospital , Addis Ababa,  Ethiopia , East Africa, 2011 – 2013

Year:

Session type:

Theme:

Yonas Girma Shumiye1

1Addis Ababa University, Addis Ababa, Ethiopia


PTMA, GLUT1, PFKFB3, BNIP3L, KCTD11 and DDB2 genes are potentially prediction markers for CCRT response of Taiwanese CRC patients

Year:

Session type:

Theme:

Shiu-Ru Lin1,Long-Sen Chang2

1Division of Medical Research, Fooyin University Hospital, Pingtung, Taiwan,2Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan


The impact of the introduction of a Palliative Macmillan Radiographer at one U.K. cancer centre

Year:

Session type:

Theme:

Rebecca Goldfinch1,Laura Pettit2

1Deanesly Centre, New Cross Hospital, Wolverhampton, UK,2Lingen Davis Cancer Centre, Royal Shrewsbury Hospital, Shrewsbury, UK


RADVAN: a randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases (ISRCTN20253034)

Year:

Session type:

Theme:

Avinash Gupta1,Adelyn Wise6,Matthew Goff6,Linda Collins6,Finn Tysoe1,Sharon Love5,Corran Roberts5,Jenny Nobes8,James Lester3,Ernie Marshall2,Carie Corner4,Mark Middleton1,7

1Oxford University Hospitals NHS Trust, Oxford, UK,2Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK,3Weston Park Hospital, Sheffield, UK,4Mount Vernon Cancer Centre, Northwood, UK,5Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, University of Oxford, Oxford, UK,6Oncology Clinical Trials Office, University of Oxford, Oxford, UK,7NIHR Oxford Biomedical Research Centre, Oxford, UK,8Norfolk and Norwich University and Hospitals NHS Foundation Trust, Norwich, UK


Multiregion copy number analysis reveals Wilms’ tumour genetic heterogeneity

Year:

Session type: , ,

Theme:

George Cresswell1,Borbala Mifsud1,John Apps2,3,Richard Williams2,3,Oystein Olsen3,Kathy Pritchard-Jones2,3,William Mifsud2,3,Nicholas M. Luscombe1

1The Francis Crick Institute, London, UK,2UCL Institute of Child Health, London, UK,3Great Ormond Street Hospital, London, UK


The use of a comprehensive low fibre diet sheet to reduce the number of radiotherapy CT planning scan attempts for patients receiving radical radiotherapy to the prostate

Year:

Session type:

Theme:

Renita Pawaroo1,Helen Corbishley1,Ian Sayers1

1New Cross, Wolverhampton, UK


DNA excision repair mediates adaptive response to low doses of ionizing radiation in C57BL/6J mice

Year:

Session type:

Theme:

Youssef Ismail1,Ronald Mitchel1,Dmitry Klokov1

1Canadian Nuclear Laboratories, Chalk River, Ontario, Canada


Molecular profiling of normal breast epithelial cells to quantify breast cancer risk

Year:

Session type:

Theme:

Natalie Shenker1,Gillian Weaver2,Luca Magnani1,Van Nguyen1,Robert Brown1,James Flanagan1

1Imperial College London, London, UK,2QCCH Milk Bank, Imperial Healthcare NHS Trust, London, UK


The challenges of genetic testing in patients diagnosed with Breast Cancer; the Kent Oncology Center experience

Year:

Session type:

Theme:

Christos Mikropoulos1,Julia Hall1,Gill Sadler1,Aaron Davies1,Charlotte Abson1

1Kent Oncology Center, Maidstone, Kent, UK,2Institute of Cancer Research, London, UK


Expression of Glucose Transporter 1 (GLUT1) is a marker for poor prognosis in Oesophageal Adenocarcinoma

Year:

Session type:

Theme:

Richard C Turkington1,5,Gerald Li2,Leanne Stevenson1,Chintapuza Chisambo3,Damian McManus3,Stephen McQuaid3,Ken Arthur3,Jacqueline James3,Manuel Salto-Tellez3,Darragh McArt2,Peter Hamilton2,Pierre Lao-Sirieix4,Rebecca C Fitzgerald4,Martin Eatock1,5,Richard D Kennedy1

1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK,2Department of Bioinformatics, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK,3Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK,4Hutchison/MRC Cancer Unit, University of Cambridge, Cambridge, UK,5Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, UK


ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukaemia cells

Year:

Session type:

Theme:

Marwan Kwok1,2,Nicholas Davies1,Angelo Agathaggelou1,Edward Smith1,Ceri Oldreive1,Eva Petermann1,Grant Stewart1,Jeff Brown3,Alan Lau4,Guy Pratt1,5,Helen Parry1,2,Malcolm Taylor1,Paul Moss1,2,Peter Hillmen6,Tatjana Stankovic1,2

1School of Cancer Sciences, University of Birmingham, Birmingham, UK,2Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, UK,3Oncology iMed, AstraZeneca Pharmaceuticals, Waltham, USA,4R&D Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, UK,5Birmingham Heartlands Hospital, Birmingham, UK,6Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK


Androgen Deprivation Therapy and Diabetes: Effects of duration and type of treatment

Year:

Session type:

Theme:

Danielle Crawley1,Hans Garmo1,Sarah Rudman2,Par Stattin3,Christel Haggstrom3,Bjorn Zethelius5,Lars Holmberg1,Jan Adolfsson4,Mieke Van Hemelrijck1

1Cancer Epidemiology Group, King’s College London, London, UK,2Department of Oncology, Guy’s and St Thomas’ NHS Trust, London, UK,3Umea University, Umea, Sweden,4Karolinska University, Stockholm, Sweden,5Uppsala University, Uppsala, Sweden


IMRT-based hypofractionated re-irradiation of progressive glioblastoma: the initial results

Year:

Session type:

Theme:

Nikhil Tanna1,Olga Kirmi1,Matthew Williams1

1Imperial College Healthcare NHS Trust, London, UK


Lipids of peripheral blood mononuclear cells for cancer detection and evaluation

Year:

Session type:

Theme:

Yuri Tadevosyan1,Gohar Hakobyan1,Tigran Torgomyan1,Mihran Lazyan1,Hasmik Davtyan1,Rafik Ghazaryan1,Knarik Alexanyan2,Yelizaveta Amirkhanyan3

1Laboratory of Regulation of Cellular Activity, Institute of Molecular Biology, National Academy of Sciences of RA, Yerevan, Armenia,21Centre of Oncology after V.Fanarjyan, MH of RA, Yerevan, Armenia,3Centre of Hematology after R.Eolyan, MH of RA, Yerevan, Armenia


Widening the Treatment Escalation Plan beyond do not attempt cardiopulmonary resuscitation decisions within the Edinburgh Cancer Centre: is this happening enough?

Year:

Session type:

Theme:

Amy Armstrong1,Jenny Smith1,Jenna Schafers1,Louise Ratcliffe1,Moray Kyle1

1NHS Lothian, Edinburgh, UK


Use of gemcitabine-loaded superparamagnetic iron oxide nanoparticles against pancreatic cancer cells in an artificial circulatory model.

Year:

Session type:

Theme:

Sumit Nandi1,Paul Sykes1,Erol Hasan1,Michael Barrow1,Eithne Costello1,Matthew Rosseinsky1,John Hunt1,Christopher Halloran1

1University of Liverpool, Liverpool, UK


Dose-escalated radiotherapy for non small cell lung cancer: association between heart dosimetry and survival in IDEAL-CRT

Year:

Session type:

Theme:

Sindu Vivekanandan1,Nicholas Counsell2,Emma Parsons3,Yenting Ngai2,Laura Hughes2,Maria Hawkins1,David Landau4,John Fenwick1

1University of Oxford, Oxford, UK,2Cancer Research UK & UCL Cancer Trials Centre, London, UK,3NCRI Radiotherapy Trials Quality Assurance Group, Northwood, UK,4Kings College London and University College London, London, UK


Radiotherapy and the risk of thromboembolic disease in men with prostate cancer

Year:

Session type:

Theme:

Cecilia Bosco1,Hans Garmo1,Pär Stattin2,Per Nilsson3,Adalsteinn Gunnlaugsson3,Jan Adolfsson4,Mieke Van Hemelrijck1

1King’s College London, London, UK,2Umea University, Umea, Sweden,3Skåne University, Malmö, Sweden,4Karolinska Institutet, Stockholm, Sweden


Intravenous delivery of oncolytic REOLYSIN to primary and secondary brain tumours

Year:

Session type:

Theme:

Adel Jebar1,Emma West1,Karen Scott1,Simon Thomson2,Rob Corns2,Julia Cockle1,Fiona Errington1,Gemma Migneco1,Matt Coffey3,Christy Ralph4,Chris Twelves4,Alan Anthony4,Steve Griffin1,Ailsa Rose1,Gerry Nuovo3,Ryan Mathew2,1,Gnanamurthy SivaKumar2,Alan Melcher1,4,Susan Short1,4

1Leeds University, Leeds, UK,2Leeds General Infirmary, Leeds, UK,3Oncolytics, Alberta, Canada,4St James’s University Hospital, Leeds, UK


Development of a consumer orientated food-safety education strategy for chemotherapy patients and family-caregivers

Year:

Session type:

Theme:

Ellen W. Evans1,Adrian C. Peters1,Simon Dawson1,Elizabeth C. Redmond1

1Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, Wales, UK


Using electronic patient records as an effective tool to screen and improve recruitment to a Phase 1 trial in non-small cell lung cancer

Year:

Session type:

Theme:

Kate Haslett2,1,Linda Ashcroft1,Marie-Claude Asselin2,Neil Bayman1,Rhidian Bramley1,Paul Burt1,Clara Chan1,Joanna Coote1,Sally Falk1,Alan Jackson2,Margaret Harris1,Glenda Laviste1,Lip Lee1,Jacqueline Livsey1,Laura Pemberton1,Hamid Sheikh1,Ben Wilson1,Fiona Blackhall1,Corinne Faivre-Finn1,2

1Christie NHS Foundation Trust, Manchester, UK,2The University of Manchester, Manchester, UK


Evidence for safety of a tumour-specific IgE antibody therapeutic candidate for ovarian cancer immunotherapy in the presence of soluble circulating tumour-associated antigen

Year:

Session type:

Theme:

Heather Bax1,Debra Josephs1,Sarah Rudman2,Louise Saul1,Giulia Pellizzari1,Paul Jones3,Claire Barton3,Ana Montes2,Hannah Gould1,James Spicer1,Sophia Karagiannis1

1King’s College London, London, UK,2Guy’s and St Thomas’ NHS Foundation Trust, London, UK,3Cancer Research UK, London, UK


Chromosomal catastrophes and punctuated evolution in colorectal carcinogenesis

Year:

Session type:

Theme:

William Cross1,Ville Mustonen3,Michal Kovac2,Simon Leedham2,Trevor Graham1,Ian Tomlinson2

1Barts Cancer Institute, London, UK,2Wellcome Trust Centre for Human Genetics, Oxford, UK,3Wellcome Trust Sanger Institute, Cambridge, UK


ENHANCED IN VIVO TUMOUR ACCUMULATION OF ANTIBODY-TARGETED TEMPERATURE-SENSITIVE LIPOSOMES BY LOCAL HEAT ACTIVATION

Year:

Session type:

Theme:

Zahraa Al-Ahmady1,Olivier Chaloin2,Kostas Kostarelos1

1Nanomedicine Lab, School of Medicine and National Graphene Institute, Faculty of Medical and Human Sciences, AV Hill Building, The University of Manchester, Manchester, UK,2Laboratoire d’Immunologie et Chimie Thérapeutiques, CNRS, Institute de Biologie Moléculaire et Cellulaire, Strasbourg, France


Single arm NCRI feasibility phase II study of CHOP in combination with ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome

Year:

Session type:

Theme:

Toby Eyre1,Ruth Clifford1,Adrian Bloor11,Lucy Boyle2,Maite Cabes1,Graham P Collins1,Stephen Devereux7,George Follows3,Christopher P Fox4,John Gribben5,Chris S Hatton1,Peter Hillmen6,Tim J Littlewood1,Helen McCarthy8,Jim Murray10,Andrew R Pettitt9,Elizabeth Soilleux1,Sharon B Love2,Corran Roberts2,Anna Schuh1,2

1Oxford University Hospitals NHS Trust, Oxford, UK,2University of Oxford, Oxford, UK,3Addenbrooke’s Hospital NHS Trust, Cambridge, UK,4Nottingham University Hospitals NHS Trust, Nottingham, UK,5Barts & the London School of Medicine & Dentistry, London, UK,6University of Leeds, Leeds, UK,7Kings College Hospital, London, UK,8Royal Bournemouth Hospital, Bournemouth, UK,9Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool, UK,10Queen Elizabeth Hospital, Birmingham, UK,11The Christie Hospital NHS Trust, Manchester, UK


TRIGGERED DOXORUBICIN RELEASE IN SOLID TUMOURS IN VIVO FROM LIPID-ZIPPER PEPTIDE HYBRID THERMOSENSITIVE VESICLES

Year:

Session type:

Theme:

Zahraa Al-Ahmady1,Cheryl Scudamore2,Kostas Kostarelos1

1† Nanomedicine Lab, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK,2Mary Lyons Centre, MRC Harwell, Harwell Science and Innovations Campus, Oxfordshire, UK


Olaparib toxicity observed using a new and improved p21 reporter mouse

Year:

Session type:

Theme:

Tanya Frangova1,Colin Henderson1,Roland Wolf1,Michael McMahon1

1University of Dundee, Dundee, UK


Defining cancer related fatigue in terms of power, with respect to quality of life

Year:

Session type:

Theme:

James Ashton1

1University of Sheffield, Sheffield, South Yorkshire, UK


Detection and analysis of ?H2AX expression by immunohistochemistry as a marker of in situ breast cancer

Year:

Session type:

Theme:

Ramon Boghozian1,Christiana Kartsonaki3,1,Ioannis Roxanis4,Russell Leek5,Adrian Harris2,Katherine Vallis1

1Department of Radiation Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford University, Oxford, UK,2Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK,3Bioinformatics Group, University of Oxford, Old Road Campus Research Building, Oxford, UK,4Department of Cellular Pathology, Oxford University Hospitals and NIHR Biomedical Research Centre Oxford, Oxford, UK,5Nuffield Division of Clinical Laboratory Science, Radcliffe Department of Medicine, University of Oxford, Oxford, UK


Psychosocial barriers to breast and cervical cancers prevention in Northern Nigeria

Year:

Session type:

Theme:

Aisha Dodo1

1Cardiff Metropolitan University, Cardiff, UK


YAP/TAZ oncoproteins in epithelial stem cells and cancerThe YAP/TAZ family of transcriptional co-activators were originally discovered by Drosophila genetics, and are now emerging as potent regulators of stem cell proliferation and tumour formation.  I will discuss how YAP/TAZ proteins are regulated during normal epithelial homeostasis and during tumour formation and progression to malignancy.  Our primary hypothesis is that YAP/TAZ proteins act as sensors of apical and basolateral polarity cues that then control the subcellular localisation of YAP/TAZ.  In stem cells, which generally lack an apical domain but are in contact with the basement membrane, YAP/TAZ proteins are nuclear and promote cell proliferation.  Similarly, loss of the apical domain during the adenoma to carcinoma transition leads to strongly nuclear YAP/TAZ localisation.  The molecular mechanisms controlling YAP/TAZ localisation will be discussed, as will conditional mouse knockouts for YAP and TAZ in epithelia.

Year:

Session type:

Theme:

Barry Thompson1

1Francis Crick Institute, London, UK


Molecular Mediators of Mammographic Density

Year:

Session type:

Theme:

Alastair Ironside1,Jenny Gomm1,Linda Haywood1,Jun Wang1,Afonso Guerra1,Claude Chelala1,Louise Jones1

1Barts Cancer Institute, London, UK


Outcomes in stage IV non-small cell lung cancer treatment: an observational study.

Year:

Session type:

Theme: ,

Carles Escriu1,2,Helen Wong1,Marie McKay1,Ernie Marshall1

1Clatterbridge Cancer Centre, Liverpool, UK,2University of Liverpool, Liverpool, UK


Personal and Public Involvement (PPI) in Cancer Research – the Northern Ireland Model

Year:

Session type:

Theme:

Margaret Grayson1,Ruth Boyd2

1NI Cancer Research Consumer Forum, Belfast, Northern Ireland, UK,2NI Cancer Trials Network, Belfast, Northern Ireland, UK


Failure pattern and survival after carmustine implants and concurrent chemo-radiation with temozolamide in newly diagnosed glioblastoma patients

Year:

Session type:

Theme:

Ravi Dandamudi1,Selvaraj Giridharan1

1The Cancer Centre, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK


Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism

Year:

Session type:

Theme:

Annie Young1,2,Jenny Phillips1,Helen Hancocks1,Catherine Hill1,Neya Joshi1,Andrea Marshall1,Joanne Grumett1,Janet Dunn1,Oliver Chapman2

1University of Warwick, Coventry, UK,2University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK


Thyroid atrophy in patients receiving Sunitinib or Pazopanib for the treatment of advanced renal cell carcinoma: A common but under-reported toxicity.

Year:

Session type:

Theme:

Georgina Elizabeth Wood2,James Albert Bennett1,2,Eirini Vrentzou1,Arnold Eric Conrad Drury1,Thomas Richard Geldart1,2

1The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK,2Poole Hospital NHS Foundation Trust, Poole, UK


Suppressing tumorigenicity of prostate cancer by FABP5 inhibitors

Year:

Session type:

Theme:

Waseem Al-Jameel1,Shiva Forootan1,Syed Hussain1,Philip Cornford1,Youqiang Ke1

1Uinversity of Liverpool, Liverpool, UK


Breast Self-Examination: To Perform, or Not to Perform – That is the Question

Year:

Session type:

Theme:

Jovita Zibudaite1,Aidas Perminas1

1Vytautas Magnus University, Kaunas, Lithuania


Investigating the possible role of FABP9 in malignant progression of prostate cancer

Year:

Session type:

Theme:

Majed Al Fayi1,Shiva Forootan1,Syed Hussain1,Youqiang Ke1

1University of Liverpool, Liverpool, UK